CD274 and cervical carcinoma: The PD-L1 is an FDA-approved predictive biomarker in cervical cancer with positive tumors eligible for single-agent pembrolizumab after progression on first-line chemotherapy (Walsh and Tan, 2021), while PD-L1 showed to be a valid predictive biomarker in OC (Zhu et al., 2021).